Table I.
Demographic, anthropometric, and clinical characteristics of the study participants
| Variable | Total | Baron score = 0 (n = 34) | Baron score ≥ 1 (n = 47) | P-value | |
|---|---|---|---|---|---|
| Sex: | 0.114 | ||||
| Male | 38 (47%) | 12 (35%) | 26 (55%) | ||
| Female | 43 (53%) | 22 (65%) | 21 (45%) | ||
| Age [years] | 15 (12–16) | 15 (13–17) | 14 (12–16) | 0.402 | |
| Age at CU diagnosis [years] | 12 (9–14) | 11 (8–14) | 12 (10–14) | 0.467 | |
| Body height [cm] | 162 (153–173) | 165 (155–174) | 159 (151–173) | 0.397 | |
| Body weight [kg] | 52.3 ± 17.4 | 54.8 ± 19.2 | 50.5 ± 15.9 | 0.275 | |
| BMI [kg/m2] | 19 (17–22) | 20 (18–22) | 19 (16–21) | 0.066 | |
| Medication history: | |||||
| 5-ASA | 75 (93%) | 32 (94%) | 43 (91%) | 0.656 | |
| Immunotherapy | 46 (57%) | 21 (62%) | 25 (53%) | 0.500 | |
| Corticosteroids | 53 (65%) | 25 (74%) | 28 (60%) | 0.240 | |
| Biologicals | 10 (12%) | 3 (9%) | 7 (15%) | 0.508 | |
| Current medications: | |||||
| 5-ASA | 77 (95%) | 32 (94%) | 45 (96%) | 0.739 | |
| Immunotherapy | 45 (56%) | 19 (56%) | 26 (55%) | 0.960 | |
| Corticosteroids | 16 (20%) | 5 (15%) | 11 923%) | 0.405 | |
| Biologicals | 9 (11%) | 2 (6%) | 7 (15%) | 0.291 | |
| Baron score: | |||||
| 0 | 34 (42%) | 34 (100%) | 0 (0%) | ||
| 1 | 27 (33%) | 0 (0%) | 27 (57%) | ||
| 2 | 14 (17%) | 0 (0%) | 14 (30%) | ||
| 3 | 6 (7%) | 0 (0%) | 6 (13%) | ||
| PUCAI score | 0 (0-20) | 0 (0-0) | 10 (0-35) | < 0.001 | |
| Paris classification – extent: | < 0.001 | ||||
| 0 | 34 (42%) | 34 (100%) | 0 (0%) | ||
| 1 | 8 (10%) | 0 (0%) | 8 (17%) | ||
| 2 | 16 (20%) | 0 (0%) | 16 (34%) | ||
| 3 | 8 (10%) | 0 (0%) | 8 (17%) | ||
| 4 | 15 (19%) | 0 (0%) | 15 (32%) | ||
| Paris classification – severity: | 0.775 | ||||
| 0 | 66 (81%) | 27 (79%) | 39 (83%) | ||
| 1 | 15 (19%) | 7 (21%) | 8 (17%) | ||